JP2019023645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019023645A5
JP2019023645A5 JP2018169294A JP2018169294A JP2019023645A5 JP 2019023645 A5 JP2019023645 A5 JP 2019023645A5 JP 2018169294 A JP2018169294 A JP 2018169294A JP 2018169294 A JP2018169294 A JP 2018169294A JP 2019023645 A5 JP2019023645 A5 JP 2019023645A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
assay
biological sample
ros
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018169294A
Other languages
English (en)
Japanese (ja)
Other versions
JP6619070B2 (ja
JP2019023645A (ja
Filing date
Publication date
Priority claimed from US13/113,676 external-priority patent/US20120208824A1/en
Application filed filed Critical
Publication of JP2019023645A publication Critical patent/JP2019023645A/ja
Publication of JP2019023645A5 publication Critical patent/JP2019023645A5/ja
Application granted granted Critical
Publication of JP6619070B2 publication Critical patent/JP6619070B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018169294A 2011-05-23 2018-09-11 肺癌におけるｒｏｓキナーゼ Active JP6619070B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/113,676 2011-05-23
US13/113,676 US20120208824A1 (en) 2006-01-20 2011-05-23 ROS Kinase in Lung Cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017173626A Division JP6404423B2 (ja) 2011-05-23 2017-09-11 肺癌におけるｒｏｓキナーゼ

Publications (3)

Publication Number Publication Date
JP2019023645A JP2019023645A (ja) 2019-02-14
JP2019023645A5 true JP2019023645A5 (https=) 2019-05-09
JP6619070B2 JP6619070B2 (ja) 2019-12-11

Family

ID=46208827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014512072A Active JP6210977B2 (ja) 2011-05-23 2012-05-23 肺癌におけるｒｏｓキナーゼ
JP2017173626A Active JP6404423B2 (ja) 2011-05-23 2017-09-11 肺癌におけるｒｏｓキナーゼ
JP2018169294A Active JP6619070B2 (ja) 2011-05-23 2018-09-11 肺癌におけるｒｏｓキナーゼ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014512072A Active JP6210977B2 (ja) 2011-05-23 2012-05-23 肺癌におけるｒｏｓキナーゼ
JP2017173626A Active JP6404423B2 (ja) 2011-05-23 2017-09-11 肺癌におけるｒｏｓキナーゼ

Country Status (13)

Country Link
US (3) US20120208824A1 (https=)
EP (3) EP3492918B1 (https=)
JP (3) JP6210977B2 (https=)
KR (1) KR102123963B1 (https=)
CN (2) CN106148525B (https=)
CA (2) CA3020650C (https=)
DK (2) DK2715365T3 (https=)
ES (2) ES2716980T3 (https=)
HU (1) HUE041780T2 (https=)
PT (1) PT3182128T (https=)
SI (1) SI3182128T1 (https=)
TR (1) TR201902690T4 (https=)
WO (1) WO2012162373A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP3266795A1 (en) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Method for detecting a fig-ros fusion polynucleotide
EP3470513B1 (en) * 2013-03-15 2020-05-13 Expression Pathology, Inc. Srm assay to indicate cancer therapy
EP3092495B1 (en) * 2014-01-06 2020-11-25 Expression Pathology, Inc. Srm assay for pd-l1
WO2017153932A1 (en) 2016-03-10 2017-09-14 Novartis Ag Strn-alk fusion as a therapeutic target in gastric cancer
WO2017175111A1 (en) 2016-04-04 2017-10-12 Novartis Ag Strn-alk fusion as a therapeutic target in colorectal cancer
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
KR101987065B1 (ko) 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
KR102167739B1 (ko) 2018-10-31 2020-10-19 한국과학기술연구원 Alk 또는 ros-1 인산화 효소 억제제 스크리닝을 위한 방법, 조성물 및 키트 및 방법
JP7313033B2 (ja) * 2019-03-01 2023-07-24 国立大学法人北海道大学 Ｉｋｚｆ１遺伝子変異を検出するための核酸プローブセット及び当該プローブセットを用いたｉｋｚｆ１遺伝子変異の検出方法
CN110632318B (zh) * 2019-10-28 2023-04-07 四川大学华西医院 Tpm3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN111440241B (zh) * 2020-05-31 2021-01-05 广东赛尔生物科技有限公司 一种包含特异性结合ros1的单克隆抗体的癌症检测试剂盒

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
ES2225816T5 (es) 1990-02-01 2014-08-21 Siemens Healthcare Diagnostics Products Gmbh Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
CA2315256A1 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US7300753B2 (en) 1998-09-04 2007-11-27 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
AU8843701A (en) 2000-09-09 2002-03-22 Univ New York State Res Found Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7313482B2 (en) 2001-05-17 2007-12-25 The Public Health Research Institute Of The City Of New York, Inc. Selection of target sites for antisense attack of RNA
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
PL375064A1 (en) 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
PL1959955T3 (pl) 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2458497T3 (es) * 2006-04-14 2014-05-05 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
PT2450437T (pt) 2006-04-14 2017-08-25 Cell Signaling Technology Inc Defeitos de genes e cinase alk mutante em tumores sólidos humanos
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
SG177225A1 (en) 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases
JP5769968B2 (ja) 2007-10-18 2015-08-26 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
EP2255190A4 (en) 2008-02-12 2011-05-04 Brigham & Womens Hospital FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER
GB2467901A (en) 2009-02-12 2010-08-18 Norgine Bv 3',6'-dihydroxy-5(6)-nitrospiro[2-benzofuran-3,9'-xanthene]-1-one mixt. by reacting 4-nitrophthalic acid/anhydride & benzene-1,3-diol in methanesulphonic acid
EP3266795A1 (en) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Method for detecting a fig-ros fusion polynucleotide
LT3009428T (lt) * 2009-05-08 2018-04-10 Astellas Pharma Inc. Diamino heterociklinis karboksamido junginys
WO2011146945A2 (en) 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer

Similar Documents

Publication Publication Date Title
JP2019023645A5 (https=)
Hoffmann et al. HPV DNA, E6* I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer–how valid is p16INK4A as surrogate marker?
JP2010259438A5 (https=)
JP2017108751A5 (https=)
TR201902690T4 (en) ROS KINASE IN LUNG CANCER.
ES2538362T3 (es) Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
JP2018019720A (ja) 前立腺癌における再発性の遺伝子融合物
JP2009039107A5 (https=)
KR102180117B1 (ko) 간암 특이적 바이오 마커
JP2009502116A5 (https=)
WO2014047285A1 (en) Identifying taxane sensitivity in prostate cancer patients
JP2008506407A5 (https=)
WO2015103166A1 (en) Prostate cancer gene profiles and methods of using the same
JP2018516533A5 (https=)
JP2011517937A5 (https=)
EP2051809A1 (en) Analyte manipulation and detection
Sinha et al. Pro-oncogenic, intra host viral quasispecies in Diffuse large B cell lymphoma patients with occult Hepatitis B Virus infection
Zou et al. Heterozygote of TAP1 Codon637 decreases susceptibility to HPV infection but increases susceptibility to esophageal cancer among the Kazakh populations
US20120004136A1 (en) Msh2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
KR20220078659A (ko) 생물학적 샘플 및 rna 안정화를 위한 조성물, 방법 및 키트
JP2012507291A5 (https=)
WO2017033905A1 (ja) Ｏｃｌｎ－ａｒｈｇａｐ２６遺伝子の検出方法
KR101670135B1 (ko) 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
JP2010187665A (ja) オキサ型β−ラクタマーゼ産生菌の検出方法、同定方法及びキット
CN120098966A (zh) 一种基于Cas蛋白改造的一管法检测系统及其应用